M-CHAT: Phreesia Digital Checklist for Autism With Touchscreen Interface

Phreesia is a leader in patient check-in, with a network of thousands of clinicians nationwide. Phreesia’s touchscreen interface makes clinicians to do what they do best.

As part of its digital check-in process, Phreesia offers an electronic version of the nationally recognized Modified Checklist for Autism in Toddlers (M-CHAT), a screening tool to assess risk for autism spectrum disorders (ASD) in toddlers aged 16 to 30 months old. The American Academy of Pediatrics (AAP) recommends that all children receive autism-specific screening at 18 and 24 months of age, in addition to broad developmental screening at 9, 18 and 24 months.

With diminishing reimbursements and rising practice costs, it is increasingly difficult for clinicians to administer clinical risk assessments to patients.  Phreesia’s comprehensive check-in solution eliminates the time-consuming administrative work from the screening process, allowing clinicians to screen more patients and effortlessly identify those who require further diagnostic evaluation. 

Since November 2010, Phreesia has screened thousands of children for ASD and has identified over 26 percent who required further evaluation.  By administering the M-CHAT electronically with Phreesia, medical practices save hours of staff time previously spent managing paper forms and scoring results, enabling them to spend more time focusing on patient care and engaging with patients in the exam room.

Says Rondie Ervin, MD, of Victory Pediatrics in Covington, Ga., “Phreesia has made the standardized developmental screening process incredibly easy for us.  We had been administering the M-CHAT on paper, which is a very cumbersome process.  With Phreesia, we’ve been able to go paperless and it automatically scores the results, which we can then upload into our system.  This saves us about 20 minutes of work per patient, and I feel confident that we are screening our patients appropriately and giving them the level of care that they need.”

Used by thousands of medical practices nationwide, Phreesia is the leader in patient check-in.  Phreesia digitizes the check-in process with an electronic, touchscreen PhreesiaPad, which patients use to enter their demographic, insurance and clinical information, as well as to pay their copayments and balances.  In addition to streamlining the check-in process, Phreesia also enhances clinical care, in part through offering a wide array of health risk assessments and other quality of care initiatives.

Says Phreesia CEO Chaim Indig, “Phreesia is proud to support pediatricians in screening their patients for ASD.  We recognize that with growing costs, it is difficult for many clinicians to administer the M-CHAT to their patients, and our technology makes it easy for them to screen all of their patients properly, while minimizing administrative costs.  Together, we can improve the efficiency and effectiveness of patient care, and help growing numbers of children get the appropriate early intervention services they need.”

Source: http://www.phreesia.com/

Diagnosis with saliva on the touch screen

Really? It may be a question that you Think when reading the title above. Only by spitting on the tablet screen or mobile phone and then let the application do all the lab work. Maybe this is the effect of the progress of the touch screen interface.

Byoung Yeon Won and Hyun Gyu Park from Korea Advanced Institute for Science and Technology suggest that all you need to do is press a tiny droplet of the sample against a phone’s touchscreen, and then an app would figure out whether you have food poisoning, strep throat, or the flu, for example. New Scientist reports.

Touchscreens sense a fingertip’s ability to store electric charge – known as its capacitance.

Turns out, the capacitive sensitivity of touchscreens is much higher than what we need on a daily basis (that is, playing games on the subway doesn’t require much sensitivity). “Since these touchscreens can detect very small capacitance changes, we thought they could serve as highly sensitive detection platforms for disease biomarkers,” Park says.

So, the duo devised a way to harness touchscreen power into a lab-on-a-chip and tried to provide some proof-of-concept.

They put drops of 3 different solutions – each containing varying concentrations of DNA from the chlamydia bacteria – onto a multitouch display the size of an iPhone’s.

With drops as small as 10 microliters, the screen was able to distinguish between the capacitances caused by each of the different concentrations of bacteria DNA.

For now, the tech can’t identify specific viruses or bacteria from the sample – but the ability to tell the difference between concentrations is a promising step.

However, any changes to current production-line touchscreens would need to demonstrate huge financial benefits before they’re implemented.

Also, the team’ll need to figure out how to eliminate false-touch signals from sweat and other kinds of moisture. And they also want to make a film that will stick on the screen: “Nobody wants direct application of bio-samples onto their phone,” Park says.


For detail report visit: http://www.newscientist.com/article/mg21228405.800-to-selfdiagnose-spit-on-an-iphone.html